IAVI 001
Status:Completed
Phase:Open Label
Principal Investigator(s):
Objective:The study compares ths afety and immunogenicity of and HIV-1 clade A DNA vaccine in healthy volunteers at low risk of HIV infections.
Prevention Option(s):HIV Vaccine
Study Design:Open label
Arms and Assigned Interventions
DescriptionDays 0 and 21, participants receive a single IM dose of 100 mg of pTHr.HIVA in 0.5mL.
Follow up at 6, 12 and 18 months.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionDays 0 and 21, participants receive a single IM dose of 500 mg of pTHr.HIVA in 1.0mL.
Follow up at 6, 12 and 18 months.
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code:
IAVI 001
Trial Sponsors:
IAVI, John Warin Ward, Medical Research Council (MRC)
Start Date
End Date
none
none
Enrollment:18
Age range:
↔
any
Population:Cisgender Men, Cisgender Women